The DETERMINE trial9 was a placebo-controlled, randomised, phase 2 trial of the anti-CTLA-4 immune checkpoint inhibitor, tremelimumab, in patients with relapsed mesothelioma. This evidence concerns the gene CTLA4 and mesothelioma.